{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:24:33Z","timestamp":1794349473413,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022XD057"],"award-info":[{"award-number":["2022XD057"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2024ZZ1008"],"award-info":[{"award-number":["2024ZZ1008"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804300"],"award-info":[{"award-number":["2022YFC2804300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22XD1423100"],"award-info":[{"award-number":["22XD1423100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222047"],"award-info":[{"award-number":["82222047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["W2411079"],"award-info":[{"award-number":["W2411079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020717","name":"Center for High Performance Computing, Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103623","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:59:00Z","timestamp":1762315140000},"page":"103623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study"],"prefix":"10.1016","volume":"90","author":[{"given":"Zhen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueze","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunpeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-1951","authenticated-orcid":false,"given":"Haojie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103623_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2025.103623_bib2","first-page":"78","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103623_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103623_bib4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","article-title":"CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity","volume":"8","author":"Hamilton","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103623_bib5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2025.103623_bib7","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2022.05.004","article-title":"Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"22","author":"Jacobs","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.eclinm.2025.103623_bib9","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103623_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2025.103623_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103623_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2215-0366(19)30298-6","article-title":"Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health","volume":"7","author":"Davis","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103623_bib13","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103623_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.eclinm.2025.103623_bib15","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/j.jtct.2025.01.604","article-title":"Post market analysis of toxicities reported with chimeric antigen receptor (CAR) T-Cell therapies and bispecific T-Cell engager (BiTE) for diffuse large B-Cell lymphoma (DLBCL) using the FDA adverse event reporting system (FAERS)","volume":"31","author":"Giese","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eclinm.2025.103623_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1434231","article-title":"CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017\u20132023)","volume":"15","author":"Shi","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103623_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.eclinm.2025.103623_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103623_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.eclinm.2025.103623_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.eclinm.2025.103623_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional Therapies\u2014Pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103623_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103623_bib24","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib26","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103623_bib27","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103623_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eclinm.2025.103623_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7861\/clinmed.2023-0391","article-title":"Lactic acidosis in a patient with cancer","volume":"23","author":"Oseguera","year":"2023","journal-title":"Clin Med"},{"key":"10.1016\/j.eclinm.2025.103623_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.130","article-title":"Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma","volume":"8","author":"Gong","year":"2024","journal-title":"Hemasphere"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:39:32Z","timestamp":1794346772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S2589537025005577"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103623","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103623"}}